Lupin's LMS commissions new Oncology Block at Vizag facility

Capex & Operations View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹1980.00

prior close

₹2011.20

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.8%+2.2% vs market

Pharmaceuticals peers, median of 157sector+0.8%+2.1% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Midcap 150 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

+0.1

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9+0.8+2.2+0.8+2.1

Next day

+3.8+0.4+3.4+0.5+3.4

+3.8+0.5+3.3+0.4+3.4

+3.7+1.2+2.6+0.4+3.3

+3.5+0.5+3.0-0.1+3.7

+2.3+0.9+1.4-0.6+2.9

+2.6-0.3+2.9-1.2+3.8

15d

+5.1-0.4+5.5-1.8+6.9

+6.7-0.3+7.0-2.6+9.3

+10.5-1.2+11.7-5.4+15.8

+12.1+0.1+12.0-6.0+18.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin Manufacturing Solutions (LMS), Lupin's wholly-owned subsidiary, has commissioned a new dedicated Oncology Block at its Vizag facility. The 4,270 sq meter unit features 20 reactors (250L to 2000L), over 20 isolators, and supports High Potent API production for oncology drugs with exposure levels at or below 0.05 micrograms per cubic meter. The facility offers batch sizes of 1-35 kg and integrates Process Development and Quality Control labs, strengthening LMS's CDMO capabilities across the oncology development lifecycle from preclinical research to commercial manufacturing.

Likely market impact

Expands Lupin's CDMO business in the growing oncology segment, adding high-potency manufacturing capacity to serve global pharma clients and potentially driving future revenue growth.